# Dual SSTR2 and Integrin αvβ3 Targeting PET/CT Imaging

> **NCT02817945** · EARLY_PHASE1 · UNKNOWN · sponsor: **Peking Union Medical College Hospital** · enrollment: 100 (estimated)

## Conditions studied

- Lung Cancer
- Neuroendocrine Neoplasm

## Interventions

- **DRUG:** 68Ga-NOTA-3P-TATE-RGD

## Key facts

- **NCT ID:** NCT02817945
- **Lead sponsor:** Peking Union Medical College Hospital
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2016-06-01
- **Primary completion:** 2020-12-01
- **Final completion:** 2022-12-31
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2022-04-07


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02817945

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02817945, "Dual SSTR2 and Integrin αvβ3 Targeting PET/CT Imaging". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02817945. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*